The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy

Danish Medical Bulletin

Volumn 58, Issue 4, 2011, Pages

  Schjoedt, Katrine Jordan ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; IRBESARTAN; LISINOPRIL; RENIN INHIBITOR; SPIRONOLACTONE;

ALBUMINURIA; ALLELE; ARTICLE; AUTOREGULATION; BLOOD PRESSURE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; DRUG EFFECT; GENOTYPE; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; ORTHOSTATIC HYPOTENSION; PRIMARY HYPERALDOSTERONISM; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 79955153971     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (238)

1. Schjoedt KJ, Andersen S, Rossing P, et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939.
2. Schjoedt KJ, Jacobsen P, Rossing K, et al. Dual Blockade of the Renin-angiotensin-aldosterone System in Diabetic Nephropathy: The Role of Aldosterone. Horm Metab Res 2005; 37, suppl 1: 4-8.
3. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836.
4. Schjoedt KJ, Lajer M, Andersen S, et al. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. Scand J Clin Lab Invest 2006; 66: 173-180.
5. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
6. Schjoedt KJ, Hansen HP, Tarnow L, et al. Long-term prevention of diabetic nephropathy: an audit. Diabetologia 2008; 51: 956-961.
7. Schjoedt KJ, Astrup AS, Persson F, et al. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia 2008; 52: 46-49.
8. Schjoedt KJ, Christensen PK, Jorsal A, et al. Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. Nephrol Dial Transplant 2009; 24: 3343-3349.
9. Parving H-H, Mauer M, Ritz E: Diabetic Nephropathy, chap. 36, in The Kidney, 8th ed., edited by Brenner BM, Philadelphia, Saunders, 2008, pp 1265-1298
10. The Danish Society of Nephrology. Danish National Registry Annual Report 2007. 2008. Ref Type: Report
11. U.S.Renal Data System, USRDS. 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. 2008. Ref Type: Report
12. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, et al. Coronary heart disease in young Type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk-factors. Diabetologia 1987; 30: 144-148.
13. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987; 294: 1651-1654.
14. Parving H-H, Hovind P, Rossing K, et al. Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001; 10: 515-522.
15. Astrup AS, Tarnow L, Rossing P, et al. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005; 68: 1250-1257.
16. Finne P, Reunanen A, Stenman S, et al. Incidence of endstage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-1787.
17. de Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
18. de Zeeuw D, Remuzzi G, Parving H-H, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
19. Rossing K, Christensen PK, Hovind P, et al. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 2005
20. Hommel E, Parving H-H, Mathiesen ER, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 1986; 293: 466-470.
21. Lewis E, Hunsicker L, Bain R, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
22. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
23. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
24. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on Renal and Cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
25. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
26. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
27. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
28. Rauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26 Suppl 1: S80-S82.
29. WHO Study Group. Diabetes mellitus. WHO. 727, 1-113. 1985. Geneva, World Health Organization. Technical Report Series 727. Ref Type: Report
30. Parving H-H. Initiation and progression of diabetic nephropathy. N Engl J Med 1996; 335: 1682-1683.
31. Hovind P, Rossing P, Tarnow L, et al. Remission of nephroticrange albuminuria in type 1 diabetic patients. Diabetes Care 2001; 24: 1972-1977.
32. Rossing P, Hommel E, Smidt UM, et al. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-516.
33. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994; 45 (suppl. 45): S174-S178.
34. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
35. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.
36. Altman DG: Clinical trials, chap. 15, in Practical Statistics for Medical Research, 1. edition ed., edited by Altman DG Chapman & Hall/CRC, 1991, pp 440-474
37. Pinhero JC, Bates DM: Mixed-effects Models in S and S-PLUS J. New York, Springer, 2000
38. Andersen S, Tarnow L, Cambien F, et al. Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE insertion/deletion genotype? Diabetes Care 2003; 26: 1501-1506.
39. Brochner-Mortensen J, Rodbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35-45.
40. Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 2007; 27: 144-152.
41. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006; 20: 239-253.
42. Hanes DS, Nahar A, Weir MR. The tissue renin-angiotensinaldosterone system in diabetes mellitus. Curr Hypertens Rep 2004; 6: 98-105.
43. Hollenberg NK, Stevanovic R, Agarwal A, et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int 2004; 65: 1435-1439.
44. Price DA, Porter LE, Gordon M, et al. The paradox of the lowrenin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382-2391.
45. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36: 449-467.
46. Price DA, De'Oliveira JM, Fisher ND, et al. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens 1999; 12: 348-355.
47. Feldt-Rasmussen B, Mathiesen ER, Deckert T, et al. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 610-617.
48. Hommel E, Mathiesen ER, Giese J, et al. On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy. Scand J Clin Lab Invest 1989; 49: 537-544.
49. O'Donnell MJ, Lawson N, Barnett AH. Activity of the unstimulated renin-angiotensin-aldosterone system in type 1 diabetic patients with and without proteinuria. Diabet Med 1989; 6: 422-425.
50. Hene RJ, Boer P, Koomans HA, et al. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101.
51. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123.
52. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20.
53. Kim GH, Masilamani S, Turner R, et al. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci U S A 1998; 95: 14552-14557.
54. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37: 677-688.
55. Lea WB, Kwak ES, Luther JM, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75: 936-944.
56. Rocha R, Chander PN, Zuckerman A, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237.
57. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068.
58. Rocha R, Chander PN, Zuckerman A, Stier CT, Jr.: Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats. (abstract) Hypertension 32 (3):598, 1998
59. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001; 94: 378-383.
60. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800.
61. Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263.
62. Romagni P, Rossi F, Guerrini L, et al. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003; 166: 345-349.
63. Ullian ME, Fine JJ. Mechanisms of enhanced angiotensin IIstimulated signal transduction in vascular smooth muscle by aldosterone. J Cell Physiol 1994; 161: 201-208.
64. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985; 63: 1522-1527.
65. Weber MA, Purdy RE. Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982; 30: 2009-2017.
66. Lieb W, Larson MG, Benjamin EJ, et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation 2009; 119: 37-43.
67. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
68. Nishizaka MK, Zaman MA, Green SA, et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004; 109: 2857-2861.
69. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-933.
70. Duffy SJ, Biegelsen ES, Eberhardt RT, et al. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 2005; 46: 707-713.
71. Oberleithner H, Riethmuller C, Schillers H, et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci U S A 2007; 104: 16281-16286.
72. Epstein M, Calhoun DA. The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Curr Hypertens Rep 2007; 9: 98-105.
73. Fujisawa G, Okada K, Muto S, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502.
74. van den Hoven MJ, Waanders F, Rops AL, et al. Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 2009; 24: 2637-2645.
75. Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 2008; 31 Suppl 2: S202-S207.
76. Stier CT, Jr., Rocha R, Chander PN. Effect of aldosterone and MR blockade on the brain and the kidney. Heart Fail Rev 2005; 10: 53-62.
77. Conn JW, Knopf RF, Nesbit RM. Clinical Characteristics of Primary Aldosteronism from an Analysis of 145 Cases. Am J Surg 1964; 107: 159-172.
78. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801-1802.
79. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232-238.
80. Ribstein J, Du CG, Fesler P, et al. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16: 1320-1325.
81. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.
82. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21: 2149-2157.
83. Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep 2008; 10: 496-503.
84. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66: 607-618.
85. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.
86. Sato A, Hayashi K, Naruse M, et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
87. Horita Y, Taura K, Taguchi T, et al. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11: 462-466.
88. Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001; 37: 1808-1812.
89. Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70-78.
90. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82: 57-61.
91. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-465.
92. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999; 1: 401-406.
93. Yoneda T, Takeda Y, Usukura M, et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20: 1329-1333.
94. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
95. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198.
96. Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164-173.
97. Lansang MC, Price DA, Laffel LM, et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001; 59: 1432-1438.
98. Brand E, Chatelain N, Mulatero P, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32: 198-204.
99. Sarzani R, Salvi F, ssi-Fulgheri P, et al. Aldosterone synthase alleles and cardiovascular phenotype in young adults. J Hum Hypertens 2003; 17: 859-864.
100. Tiago AD, Badenhorst D, Nkeh B, et al. Impact of reninangiotensin-aldosterone system gene variants on the severity of hypertension in patients with newly diagnosed hypertension. Am J Hypertens 2003; 16: 1006-1010.
101. Davies E, Holloway CD, Ingram MC, et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999; 33: 703-707.
102. Sookoian S, Gianotti TF, Gonzalez CD, et al. Association of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis. J Hypertens 2007; 25: 5-13.
103. Staessen JA, Li Y, Thijs L. Meta-analysis of blood pressure and the CYP11B2 polymorphism highlights the need for better designed studies. J Hypertens 2007; 25: 37-39.
104. Kurland L, Melhus H, Karlsson J, et al. Aldosterone synthase (CYP11B2)-344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15: 389-393.
105. Lajer M, Schjoedt KJ, Jacobsen P, et al. Aldosterone synthase (CYP11B2)-344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabet Med 2006; 23: 675-680.
106. Lovati E, Richard A, Frey BM, et al. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 2001; 60: 46-54.
107. Furumatsu Y, Nagasawa Y, Tomida K, et al. Effect of reninangiotensin-aldosterone system triple blockade on nondiabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31: 59-67.
108. Ko GJ, Kang YS, Lee MH, et al. Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients. Nephrology (Carlton) 2008; 13: 492-499.
109. Hovind P, Tarnow L, Rossing P, et al. Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2004; 66: 1180-1186.
110. Parving H-H, Oxenboll B, Svendsen PAa, et al. Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol 1982; 100: 550-555.
111. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; i: 1430-1432.
112. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93.
113. Mathiesen ER, Oxenboll B, Johansen K, et al. Incipient nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1984; 26: 406-410.
114. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; ii: 1300-1304.
115. Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988; 297: 1092-1095.
116. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. Br Med J 1991; 303: 81-87.
117. Bangstad H-J, Osterby R, Dahl-Jorgensen K, et al. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994; 37: 483-490.
118. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-593.
119. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21: 104-110.
120. Mathiesen ER, Hommel E, Hansen HP, et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 1999; 319: 24-25.
121. Viberti GC, Mogensen CE, Groop L, et al. Effect of Captopril on progression to clinical proteinuria in patients with insulindependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275-279.
122. Laffel LMB, McGill JB, Gans JD. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995; 99: 497-504.
123. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
124. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann Intern Med 2001; 134: 370-379.
125. Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-1084.
126. Hansen HP, Lund SS, Rossing P, et al. Preventing diabetic nephropathy: an audit. Scand J Clin Lab Invest 2001; 61: 471-477.
127. Suissa S, Hutchinson T, Brophy JM, et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
128. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996; 156: 286-289.
129. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 1994; 45 (suppl. 45): S150-S155.
130. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulindependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J hypertens 1995; 8: 876-883.
131. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
132. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with type 2 Diabetes. N Engl J Med 2001; 345: 870-878.
133. Bjorck S, Mulec H, Johnsen SAa, et al. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 339-343.
134. Kasiske BL, Kalil R, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 1993; 118: 129-138.
135. Cirillo VJ, Gomez HJ, Salonen J, et al. Lisinopril: dose-peak effect relationship in essential hypertension. Br J Clin Pharmacol 1988; 25: 533-538.
136. Gomez HJ, Cirillo VJ, Sromovsky JA, et al. Lisinopril doseresponse relationship in essential hypertension. Br J Clin Pharmacol 1989; 28: 415-420.
137. Andersen S, Rossing P, Juhl TR, et al. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1413-1418.
138. Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926.
139. Rossing K, Christensen PK, Hansen BV, et al. Optimal dose of Candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized crossover study. Diabetes Care 2003; 26: 150-155.
140. Schmieder RE, Klingbeil AU, Fleischmann EH, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005; 16: 3038-3045.
141. Laverman GD, Navis G, Henning RH, et al. Dual reninangiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62: 1020-1025.
142. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440-1444.
143. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273-277.
144. Sengul AM, Altuntas Y, Kurklu A, et al. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 2006; 71: 210-219.
145. Rossing K, Christensen PK, Jensen BR, et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25: 95-100.
146. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002; 17: 1019-1024.
147. Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-2274.
148. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63: 1874-1880.
149. Tylicki L, Renke M, Rutkowski P, et al. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study. Scand J Urol Nephrol 2008; 42: 381-388.
150. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392.
151. Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992-999.
152. Wolf G. "The road not taken": role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant 2002; 17: 195-198.
153. Wolf G, Neilson EG. From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Exp Nephrol 1996; 4 Suppl 1: 8-19.
154. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction? Circulation 2008; 118: 2523-2532.
155. Cao Z, Bonnet F, Candido R, et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002; 13: 1773-1787.
156. Rossing K. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring. Dan Med Bull 2007; 54: 79-98.
157. Kuriyama S, Tomonari H, Tokudome G, et al. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002; 25: 849-855.
158. Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. Int J Clin Pract 2004; 58: 432-435.
159. Fujisawa T, Ikegami H, Ono M, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens 2005; 18: 13-17.
160. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72: 879-885.
161. Hebert LA, Falkenhain ME, Nahman NS, Jr., et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999; 19: 1-6.
162. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001; 59: 2282-2289.
163. Song JH, Lee SW, Suh JH, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003; 60: 318-326.
164. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.
165. Nakao N, Yoshimura A, Morita H, et al. Combination therapy of angiotensin-II receptor blocker and angiotensin-cenverting enzyme inhibitor in non-diabetic renal disease: a randomized, controlled trial in Japan (COOPERATE). Lancet 2003; 361: 117-124.
166. Kunz R, Wolbers M, Glass T, et al. The COOPERATE trial: a letter of concern. Lancet 2008; 371: 1575-1576.
167. Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol 2006; 26: 629, 632.
168. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
169. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
170. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet 2008; 372: 511-512.
171. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
172. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925-926.
173. Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, doublemasked, cross-over study. Diabetes Care 2005; 28: 2106-2112.
174. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
175. Davidson MB, Wong A, Hamrahian AH, et al. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract 2008; 14: 985-992.
176. Saklayen MG, Gyebi LK, Tasosa J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial. J Investig Med 2008; 56: 714-719.
177. Ustundag A, Tugrul A, Ustundag S, et al. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail 2008; 30: 982-991.
178. Chrysostomou A, Pedagogos E, MacGregor L, et al. Doubleblind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensinconverting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
179. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24: 2285-2292.
180. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-493.
181. Bomback AS, Kshirsagar AV, Amamoo MA, et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211.
182. Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-551.
183. Brenner BM, Hostetter TH, Humes HD. Molecular basis of proteinuria of glomerular origin. N Engl J Med 1978; 298: 826-833.
184. D'Amico G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63: 809-825.
185. Rippe B. What is the role of albumin in proteinuric glomerulopathies? Nephrol Dial Transplant 2004; 19: 1-5.
186. Andersen S, Blouch K, Bialek J, et al. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000; 58: 2129-2137.
187. Dworkin LD, Hostetter TH, Rennke HG, et al. Hemodynamic basis for glomerular injury in rats with desoxycorticosteronesalt hypertension. J Clin Invest 1984; 73: 1448-1461.
188. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
189. Imanishi M, Yoshioka K, Konishi Y, et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999; 42: 999-1005.
190. Renke M, Tylicki L, Knap N, et al. Spironolactone attenuates oxidative stress in patients with chronic kidney disease. Hypertension 2008; 52: e132-e133.
191. Bendtzen K, Hansen PR, Rieneck K. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 2003; 134: 151-158.
192. Han KH, Kang YS, Han SY, et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006; 70: 111-120.
193. Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.
194. Loutzenhiser R, Griffin K, Williamson G, et al. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1153-R1167.
195. Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793-800.
196. Kvam FI, Ofstad J, Iversen BM. Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR. Am J Physiol 1998; 275: F576-F584.
197. Christensen PK, Lund S, Parving H-H. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney Int 2001; 60: 1435-1442.
198. Christensen PK, Akram K, Konig KB, et al. Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. Diabetes Care 2003; 26: 156-162.
199. Delles C, Klingbeil AU, Schneider MP, et al. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 2003; 16: 1030-1035.
200. Ito S, Arima S, Ren YL, et al. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 1993; 91: 2012-2019.
201. Meyer TW, Brenner BM. The contribution of glomerular hemodynamic alterations to progressive renal disease. Contemporary Issues in Nephrology 1986; 14: 1-16.
202. Schmidt BM, Sammer U, Fleischmann I, et al. Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 47: 650-655.
203. Parving H-H, Kastrup J, Smidt UM, et al. Impaired autoregulation of glomerular filtration rate in Type 1 (insulindependent) diabetic patients with nephropathy. Diabetologia 1984; 27: 547-552.
204. Christensen PK, Hansen HP, Parving H-H. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 1997; 52: 1369-1374.
205. Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. Am J Med Sci 2001; 321: 388-400.
206. Brod J, Horbach L, Just H, et al. Acute effects of clonidine on central and peripheral haemodynamics and plasma renin activity. Eur J Clin Pharm 1972; 4: 107-114.
207. Onesti G, Schwartz AB, Kim KE, et al. Antihypertensive effect of clonidine. Circ Res 1971; 28: 53-69.
208. Kim YS, Immink RV, Stok WJ, et al. Dynamic cerebral autoregulatory capacity is affected early in Type 2 diabetes. Clin Sci (Lond) 2008; 115: 255-262.
209. Christensen PK, Lund S, Parving H-H. The impact of glycaemic control on autoregulation of glomerular filtration rate in patients with non-insulin dependent diabetes. Scand J Clin Lab Invest 2001; 61: 43-50.
210. Kim YS, Krogh-Madsen R, Rasmussen P, et al. Effects of hyperglycemia on the cerebrovascular response to rhythmic handgrip exercise. Am J Physiol Heart Circ Physiol 2007; 293: H467-H473.
211. Effectiveness of spironolactone added to an angiotensinconverting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
212. Rachmani R, Slavachevsky I, Amit M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475.
213. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
214. Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. Br J Clin Pharmacol 2004; 58: 554-557.
215. Anton C, Cox AR, Watson RD, et al. The safety of spironolactone treatment in patients with heart failure. J Clin Pharm Ther 2003; 28: 285-287.
216. Lopes RJ, Lourenco AP, Mascarenhas J, et al. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol 2008; 31: 509-513.
217. McMurray JJ, O'Meara E. Treatment of heart failure with spironolactone--trial and tribulations. N Engl J Med 2004; 351: 526-528.
218. Williams EM, Katholi RE, Karambelas MR. Use and side-effect profile of spironolactone in a private cardiologist's practice. Clin Cardiol 2006; 29: 149-153.
219. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351: 585-592.
220. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31: 153-158.
221. Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am heart J 2005; 150: 426-433.
222. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-716.
223. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123.
224. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838.
225. Epstein M, Buckalew V, Martinez F et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. (abstract) Am J Hypertens. 15 (4, supplement 1):A24, 2002
226. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
227. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425-431.
228. Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685.
229. Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16: 474-481.
230. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
231. Musini VM, Fortin PM, Bassett K, et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008 CD007066.
232. Parving H-H, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
233. Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73: 1419-1425.
234. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1-E8.
235. Luetscher JA, Kraemer FB. Microalbuminuria and increased plasma prorenin. Prevalence in diabetics followed up for four years. Arch Intern Med 1988; 148: 937-941.
236. Luetscher JA, Kramer FB, Wilson DM, et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417.
237. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
238. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136.